The KAIROS rapid platform AST (Antibiotic Susceptibility Testing) device represents a breakthrough for patients battling UTIs, sepsis, and meningitis. It empowers doctors to identify the most effective antibiotic to combat an infection. Unlike traditional tests that can take days, rapid AST characterized quick and personalized therapeutic decisions, enabling doctors to initiate appropriate treatment sooner. This translates to improved patient care, increased chances of recovery for patients and reduction in healthcare costs. Catharina Hospital, TU/e, and ShanX Medtech are collaborating to advance this much-needed device and assess its implementation in clinical settings.